Indeed, one patient did not respond to MoAbs by virtue of the absence of PTEN expression limited to the metastatic lesion in a context of a molecular profile proficient to MoAb response (EGFR CNG and no additional alterations in EGFR downstream pathways in both primary tumour and metastasis). The gene discussed is EGFR; the disease is neoplasm.